All In Biotech

Drug Trial Radar · NCT07113522

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics With Multiple Therapies in Participants With Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD)

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Apr 30, 2027

Study completion Feb 4, 2028

Sponsor

Lead sponsor
Mirador Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

Conditions

  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis (UC)
  • Crohn's Disease

Interventions

  • MT-501Drug

    MT-501

  • MT-201Drug

    MT-201

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the proportion of participants reporting treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) leading to discontinuation, and markedly abnormal laboratory valuesTime frame: Up to 13 weeks
  2. Assess the Proportion of Participants with Endoscopic Response (CD)Time frame: 13 weeks
  3. Assess the Proportion of Participants Endoscopic Improvement (UC)Time frame: 12 weeks
  4. Assess the Proportion of Participants with Clinical Remission (CD)Time frame: 13 weeks
  5. Assess the Proportion of Participants with Clinical Remission (UC)Time frame: 12 weeks

Locations

66 sites in 5 countries. Site status is shown where the registry gives one.

  • Mirador Therapeutics Selected Site

    Birmingham, Alabama · Recruiting

  • Mirador Therapeutics Selected Site

    Scottsdale, Arizona · Recruiting

  • Mirador Therapeutics Selected Site

    Sun City, Arizona · Recruiting

  • Mirador Therapeutics Selected Site

    Little Rock, Arkansas · Recruiting

  • Mirador Therapeutics Selected Site

    Little Rock, Arkansas · Recruiting

  • Mirador Therapeutics Selected Site

    Colorado Springs, Colorado · Recruiting

  • Mirador Therapeutics Selected Site

    Littleton, Colorado · Recruiting

  • Mirador Therapeutics Selected Site

    Miami, Florida · Recruiting

  • Mirador Therapeutics Selected Site

    Miami, Florida · Recruiting

  • Mirador Therapeutics Selected Site

    Miami, Florida · Recruiting

  • Mirador Therapeutics Selected Site

    Orlando, Florida · Recruiting

  • Mirador Therapeutics Selected Site

    Palmetto Bay, Florida · Recruiting

  • Mirador Therapeutics Selected Site

    Pensacola, Florida · Recruiting

  • Mirador Therapeutics Selected Site

    Atlanta, Georgia · Recruiting

  • Mirador Therapeutics Selected Site

    Snellville, Georgia · Recruiting

  • Mirador Therapeutics Selected Site

    Glenview, Illinois · Recruiting

  • Mirador Therapeutics Selected Site

    Gurnee, Illinois · Recruiting

  • Mirador Therapeutics Selected Site

    Lafayette, Louisiana · Recruiting

  • Mirador Therapeutics Selected Site

    Marrero, Louisiana · Recruiting

  • Mirador Therapeutics Selected Site

    Shreveport, Louisiana · Recruiting

  • Mirador Therapeutics Selected Site

    Ypsilanti, Michigan · Recruiting

  • Mirador Therapeutics Selected Site

    Bridgeton, Missouri · Recruiting

  • Mirador Therapeutics Selected Site

    Kansas City, Missouri · Recruiting

  • Mirador Therapeutics Selected Site

    Liberty, Missouri · Recruiting

  • Mirador Therapeutics Selected Site

    Las Vegas, Nevada · Recruiting

  • Mirador Therapeutics Selected Site

    New York, New York · Recruiting

  • Mirador Therapeutics Selected Site

    Rochester, New York · Recruiting

  • Mirador Therapeutics Selected Site

    High Point, North Carolina · Recruiting

  • Mirador Therapeutics Selected Site

    Raleigh, North Carolina · Recruiting

  • Mirador Therapeutics Selected Site

    Cincinnati, Ohio · Recruiting

  • Mirador Therapeutics Selected Site

    Liberty Township, Ohio · Recruiting

  • Mirador Therapeutics Selected Site

    Providence, Rhode Island · Recruiting

  • Mirador Therapeutics Selected Site

    Greenville, South Carolina · Recruiting

  • Mirador Therapeutics Selected Site

    Cordova, Tennessee · Recruiting

  • Mirador Therapeutics Selected Site

    Dallas, Texas · Recruiting

  • Mirador Therapeutics Selected Site

    Garland, Texas · Recruiting

  • Mirador Therapeutics Selected Site

    Georgetown, Texas · Recruiting

  • Mirador Therapeutics Selected Site

    Houston, Texas · Recruiting

  • Mirador Therapeutics Selected Site

    Lubbock, Texas · Recruiting

  • Mirador Therapeutics Selected Site

    Southlake, Texas · Recruiting

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.